This is required continuation round 2 in the same session.

Hard boundaries:

- This remains a read-only conference pass. Do not edit source, contract,
  medical-writing, product, or real-project files.
- Runner-managed report path: `runs/conference/medical_monitoring_r4_d02_cm_contract_20260811/general_grok45_round2.md`. Return the report in your final response; do not write that file with tools.

Initial read set:
  - `reviews/medical_monitoring_r4_d02_cm_slice_contract_v1_20260811.md`
  - `reviews/medical_monitoring_r4_risk_coverage_matrix_v1_20260810.md`
  - `poc/medical_monitoring_ai_native_r4/src/mm_r4/contracts.py`
  - `poc/medical_monitoring_ai_native_r4/src/mm_r4/lifecycle.py`
  - `poc/medical_monitoring_ai_native_r4/src/mm_r4/aemh.py`

Do not restart the task or open a new session. Your first response stopped with
`stopReason=cancelled` after only process narration and contained no findings or
verdict. Complete the engineering/identity/coverage adversarial review now from
the source material you already read. Do not spend this pass repeating broad
reconnaissance.

At minimum resolve these concrete interface questions:

1. State the exact structural fields/properties required by a public
   `RiskDomainUnitResult` protocol so `lifecycle.py` no longer depends on
   `AEMHUnitResult` or `.medical_grading`, while D01 behavior remains byte-for-
   behavior equivalent. Cover candidate/ref identity verification, monitoring
   priority, linked-negative closure, supersession, and competing identities.
2. Prove or reject the D02 unit decomposition for one compound CM record that
   has a confirmed prohibited ingredient and an unresolved second component;
   specify record-level aggregation without hiding the unresolved unit.
3. Specify stable clinical-event identity separately from rule/dictionary/
   mapping/algorithm lineage so an ordinary N+1 data correction is not falsely
   treated as a new risk, while a lineage change is superseded and competing
   bindings become `identity_ambiguous`.
4. Define the exact ownership/join for D02 `cm_indication` evidence consumed by
   D01 so it shares the source locator but cannot duplicate D01 candidates,
   risk instances, Query counts, or lifecycle.
5. Identify any missing contract tests for L1 exclusivity, L2 count separation,
   interval endpoints/partial dates, CM-vs-IP/EX ambiguity, Query/journey joins,
   and parallel file ownership.

For every issue cite the draft/source clause, give a counterexample or interface
failure, mark blocking/non-blocking, and propose precise replacement wording
plus deterministic tests. Return the complete Markdown report using the original
six-section output schema and end with exactly one verdict: `ACCEPT`,
`ACCEPT_WITH_GAPS`, or `VETO`. Keep evidence, inference, recommendation, and
uncertainty separate. Codex remains the final authority.
